Elevated IREB2 expression correlated with accelerated lung‐function decline in COPD but predicted improved prognosis in lung cancer B cells, whereas higher CD27+ B cell levels in COPD were associated with protumorigenic activity. Here, IREB2 is linked to lung cancer.